Sunstone portfolio company Galecto in successful IPO on Nasdaq Global Market in the US.

by | Oct 30, 2020

Sunstone today announced its portfolio company Galecto, a clinical stage biotech firm focusing on novel therapeutics for fibrosis and inflammatory-related lung diseases, successfully has launched an initial public offering (IPO) on Nasdaq Global Market in the U.S.


Press inquiries should be adressed to:

Søren Lemonius

Managing General Partner